IDEAYA Biosciences Q3 net income beats estimates

IDEAYA Biosciences

04/11/2025 11:11

Overview

IDEAYA Q3 net income of $119.2 mln, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong financial performance

Collaboration revenue for Q3 at $207.8 mln, driven by Servier agreement

Outlook

IDEAYA to report PFS data for darovasertib trial by end of 2025 to Q1 2026

IDEAYA plans Phase 3 trial for darovasertib as adjuvant therapy in H1 2026

IDEAYA expects clinical update for IDE397 and Trodelvy combo in H1 2026

Result Drivers

SERVIER AGREEMENT - $210 mln upfront payment from exclusive license agreement with Servier for darovasertib rights outside the US

CASH POSITION - IDEAYA's cash and marketable securities increased to $1.14 bln, expected to fund operations into 2030

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$207.83 mln
Q3 EPS
Beat
$1.35
-$0.54 (16 Analysts)
Q3 Net Income
Beat
$119.24 mln
-$45.13 mln (14 Analysts)
Q3 Profit From Operations
Beat
$108.45 mln
-$56.61 mln (14 Analysts)
Q3 Operating Expenses
$99.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $45.00, about 30.3% above its November 3 closing price of $31.36

Press Release: ID:nPn18TcKza

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)